Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share

v3.21.1
Net Loss Per Share
3 Months Ended
Mar. 31, 2021
Net Loss Per Share  
Net Loss Per Share

11. Net Loss Per Share

Basic net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the periods. Fully diluted net loss per common share is computed using the weighted average number of common and dilutive common equivalent shares outstanding during the periods. Common equivalent shares consist of stock options and warrants that are computed using the treasury stock method.

For the quarters ended March 31, 2021 and 2020, all of the Company’s common stock options, unvested restricted stock units and warrants are anti-dilutive and therefore have been excluded from the diluted calculation.

The following table reconciles net loss to net loss attributable to Heat Biologics, Inc.:

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended

 

 

March 31,

 

    

2021

    

2020

Net loss

 

$

(7,623,140)

 

$

(6,373,420)

Net loss - Non-controlling interest

 

 

(90,962)

 

 

(81,314)

Net loss attributable to Heat Biologics, Inc.

 

$

(7,532,178)

 

$

(6,292,106)

 

 

 

 

 

 

 

Weighted-average common shares outstanding, basic and diluted

 

 

24,199,916

 

 

8,183,154

Net loss per share, basic and diluted

 

$

(0.31)

 

$

(0.77)

 

The following potentially dilutive securities were excluded from the calculation of diluted net loss per share in the three months ended March 31, 2021 and 2020 due to their anti-dilutive effect:

 

 

 

 

 

 

 

    

2021

    

2020

Outstanding stock options

 

1,697,910

 

799,288

Restricted stock subject to forfeiture and restricted stock units

 

259,874

 

289,321

Outstanding common stock warrants

 

747,383

 

825,581